切换至 "中华医学电子期刊资源库"

中华脑血管病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (05) : 356 -359. doi: 10.11817/j.issn.1673-9248.2022.05.013

综述

心肌病相关缺血性卒中诊治进展
李颖1, 漆学良2, 冯立群1, 刘彤3, 刘广志1,()   
  1. 1. 100092 首都医科大学附属北京安贞医院神经内科
    2. 100092 首都医科大学附属北京安贞医院心内科
    3. 330006 南昌大学第二附属医院神经内科
  • 收稿日期:2021-12-29 出版日期:2022-10-01
  • 通信作者: 刘广志

Research progress in diagnosis and treatment of cardiomyopathy-related ischemic stroke

Ying Li1, Xueliang Qi2, Liqun Feng1, Tong Liu3, Guangzhi Liu1,()   

  1. 1. Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100092, China
    2. Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
    3. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100092, China
  • Received:2021-12-29 Published:2022-10-01
  • Corresponding author: Guangzhi Liu
引用本文:

李颖, 漆学良, 冯立群, 刘彤, 刘广志. 心肌病相关缺血性卒中诊治进展[J/OL]. 中华脑血管病杂志(电子版), 2022, 16(05): 356-359.

Ying Li, Xueliang Qi, Liqun Feng, Tong Liu, Guangzhi Liu. Research progress in diagnosis and treatment of cardiomyopathy-related ischemic stroke[J/OL]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(05): 356-359.

心肌病主要分为肥厚型心肌病(家族性、非家族性)、扩张型心肌病(家族性、非家族性)、限制型心肌病(家族性、非家族性)、致心律失常性右心室心肌病以及未定型心肌病(包括左心室致密化不全、Takotsubo心肌病),每种心肌病相关缺血性脑卒中风险、治疗时机及疗程各不相同。本文通过总结各类心肌病的临床特点、发病率、导致栓塞危险因素以指导心肌病相关性缺血性卒中的治疗。

The cardiomyopathy can be divided into hypertrophic cardiomyopathy (familial, non-familial), dilated cardiomyopathy (familial, non-familial), restrictive cardiomyopathy (familial, non-familial), arrhythmogenic right ventricular cardiomyopathy, and unclassified cardiomyopathy (including left ventricular noncompaction and Takotsubo cardiomyopathy). For the cardiomyopathy-associated ischemic stroke patients, risk factors of stroke, treatment timing, and the course vary substantially. This article reviews the clinical characteristics, incidence, risk factors for embolism in various cardiomyopathies to guide the treatment of the related ischemic stroke.

13
Wlodarska EK, Wozniak O, Konka M, et al. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy [J]. Europace, 2006, 8(8): 596-600.
14
Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy [J]. Lancet, 2015, 386(9995): 813-825.
15
Yacoub HA, Sivakumar K, El-Hunjul M, et al. Ischemic stroke secondary to left ventricular noncompaction [J]. J Neurol Res, 2019, 9(4-5): 75-80.
16
Lee GH, Kim DK, Song YJ, et al. Stroke in a young individual with left ventricular noncompaction and left atrium standstill [J]. Korean Circ J, 2015, 45(5): 432-438.
17
Pöyhönen P, Kuusisto J, Järvinen V, et al. Left ventricular non-compaction as a potential source for cryptogenic ischemic stroke in the young: a case-control study [J]. PLoS One, 2020, 5(8): e0237228.
18
Aung N, Doimo S, Ricci F, et al. Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies [J]. Circ Cardiovasc Imaging, 2020, 13(1): e009712.
19
Y-Hassan S, Tornvall P. Epidemiology, pathogenesis, and management of takotsubo syndrome [J]. Clin Auton Res, 2018, 28(1): 53-65.
20
Kurisu S, Inoue I, Kawagoe T, et al. Incidence and treatment of left ventricular apical thrombosis in Takotsubo cardiomyopathy [J]. Int J Cardiol, 2011, 146(3): e58-e60.
21
Y-Hassan S, Holmin S, Abdula G, et al. Thrombo-embolic complications in takotsubo syndrome: review and demonstration of an illustrative case [J]. Clin Cardiol, 2019, 42(2): 312-319.
22
Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy [J]. J Am Soc Echocardiogr, 2004, 17(6): 644-648.
23
Guttmann OP, Pavlou M, O'Mahony C, et al. Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA) [J]. Eur J Heart Fail, 2015, 17(8): 837-845.
24
Kozdag G, Ciftci E, Vural A, et al. Silent cerebral infarction in patients with dilated cardiomyopathy: echocardiographic correlates [J]. Int J Cardiol, 2006, 107(3): 376-381.
25
Mandaliya R, Boigon M, Nweke N, et al. Left ventricular non-compaction syndrome misdiagnosed as dilated cardiomyopathy on several occasions, presenting with recurrent stroke [J]. Cardiol Res, 2014, 5(1): 42-47.
26
Matsuzono K, Ikeda Y, Deguchi S, et al. Cerebral embolic stroke after disappearing takotsubo cardiomyopathy [J]. J Stroke Cerebrovasc Dis, 2013, 22(8): e682-e683.
27
de Gregorio C. Cardioembolic outcomes in stress-related cardiomyopathy complicated by ventricular thrombus:a systematic review of 26 clinical studies [J]. Int J Cardiol, 2010, 141(1): 11-17.
28
Otani Y, Tokunaga K, Kawauchi S, et al. Cerebral infarction arising from takotsubo cardiomyopathy: case report and literature review [J]. NMC Case Rep J, 2016, 3(4): 119-123.
29
Santoro F, Stiermaier T, Tarantino N, et al. Left ventricular thrombi in takotsubo syndrome: incidence,predictors,and management: results from the GEIST (German Italian Stress Cardiomyopathy) registry [J]. J Am Heart Assoc, 2017, 6(12): e006990.
30
Jung H, Yang PS, Sung JH, et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study [J]. Thromb Haemost, 2019, 119(2): 285-293.
31
Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation [J]. Int J Cardiol, 2017, 248: 232-238.
32
Rujirachun P, Charoenngam N, Wattanachayakul P, et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis [J]. Acta Cardiol, 2020, 75(8): 724-731.
1
Masarone D, Kaski JP, Pacileo G, et al. Epidemiology and clinical aspects of genetic cardiomyopathies [J]. Heart Fail Clin, 2018, 14(2): 119-128.
2
Ana CF, Joao PM, Daniela P, et al. Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance [J]. Neurology, 2020, 94(1): e107-e113.
3
中华医学会心血管病学分会中国成人肥厚性心肌病诊断与治疗指南编写组, 中华心血管病杂志编辑委员会. 中国成人肥厚型心肌病诊断与治疗指南 [J]. 中华心血管病杂志, 2017, 45(12): 1015-1032.
4
Falasconi G, Pannone L, Slavich M, et al. Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology, diagnosis and management [J]. Am J Cardiovasc Dis, 2020, 10(4): 409-418.
5
Haruki S, Minami Y, Hagiwara N. Stroke and embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation [J]. Stroke, 2016, 47(4): 936-942.
6
Gottdiener JS, Gay JA, VanVoorhees L, et al. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography [J]. Am J Cardiol, 1983, 52(10): 1281-1285.
7
Sharma ND, McCullough PA, Philbin EF, et al. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction [J]. Chest, 2000, 117(2): 314-320.
8
Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis [J]. Circulation, 2007, 116(21): 2420-2426.
9
Zubkov AY, Rabinstein AA, Dispenzieri A, et al. Primary systemic amyloidosis with ischemic stroke as a presenting complication [J]. Neurology, 2007, 69(11): 1136-1141.
10
Ammash NM, Seward JB, Bailey KR, et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy [J]. Circulation, 2000, 101(21): 2490-2496.
11
Sayed A, Pal S, Poplawska M, et al. Arrhythmogenic right ventricular cardiomyopathy diagnosis [J]. Cardiol Rev, 2020, 28(6): 319-324.
12
Hamilton-Craig C, McGavigan A, Semsarian C, et al. The Cardiac Society of Australia and New Zealand Position Statement on the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy (2019 Update) [J]. Heart Lung Circ, 2020, 29(1): 40-48.
[1] 夏靖涵, 林凤娇, 王胰, 丁戈琦, 张清凤, 张红梅, 谢盛华, 李明星, 尹立雪, 李文华. 二尖瓣空间变化联合左心房应变对肥厚型心肌病合并左心室流出道梗阻的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 585-592.
[2] 王岚, 徐斌胜, 谢乐. 肥厚型心肌病的经胸超声心动图诊断与心电图表现特征[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 593-596.
[3] 张霞, 张瑞, 郑志波, 张勤. 紫草素调控乳酸化修饰和线粒体功能改善脓毒症心肌病小鼠的预后[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 275-284.
[4] 吴姗姗, 潘裕民, 刘晋, 张劲松, 乔莉. 睡眠呼吸暂停综合征患者静脉血栓栓塞症发生率的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 312-317.
[5] 姚金含, 王伟娜, 张玉泉. 妊娠相关深静脉血栓形成患者的预后研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 367-373.
[6] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[7] 张春玉, 陈海云, 肖忠萍, 罗琴, 潘运昌. 血清NT-proBNP 预测肺栓塞心脏功能障碍的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 805-808.
[8] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[9] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10] 刘华亭, 张媛, 张登文, 王杰, 袁阳. 介入栓塞联合手术切除治疗头皮动静脉畸形的疗效观察[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 273-278.
[11] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[12] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[13] 于洁, 金小红, 顾艳楣, 王慧, 葛杨杨, 李燕. 癌症相关静脉血栓栓塞症患者疾病体验与需求的质性研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 739-744.
[14] 崔伟, 邓屹, 叶苏意, 李静, 陈晓明, 张靖, 许荣德. 载药微球支气管动脉化疗栓塞术治疗罕见非小细胞肺癌的临床疗效和安全性分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 303-310.
[15] 耿晓坤. 缺血性卒中后无效再灌注的时间窗、组织窗与神经保护[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(06): 636-636.
阅读次数
全文


摘要